ReviewF1000Research2017
Update on ventilator-associated pneumonia.
Review in F1000Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 131 citations in OpenAlex.
- Risk factors and outcomes of ventilator-associated pneumonia: an updated systematic review and meta-analysis.BMC pulmonary medicine · 2025Pooled it
- Pooled it
- Randomized Clinical Study of Temporary Transvenous Phrenic Nerve Stimulation in Difficult-to-Wean Patients.American journal of respiratory and critical care medicine · 2022Trial
- Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial.Critical care (London, England) · 2019Trial
- Mortality and Predictors of In-Hospital Death Among Mechanically Ventilated Adults With Gram-Negative Pneumonia.Cureus · 2026Article
- Clinical outcomes of diaphragm pacing in facilitating weaning from mechanical ventilation: a systematic review and meta-analysis.Journal of thoracic disease · 2026Article
- Mortality in Ventilator-Associated Tracheobronchitis and Pneumonia in Oncology Patients: The Impact of Microbiological Aspects.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Analyzing the effects of benzodiazepines on the virulence and biofilm formation of Pseudomonas aeruginosa.Scientific reports · 2025Article
- Indole-Acetic Acid Impairs Pseudomonas aeruginosa Virulence and Alters Lung Infection in Mice.MicrobiologyOpen · 2025Article
- Oropharyngeal Interventions in Intubated Patients for Preventing Ventilator Associated Pneumonia: A Systematic Review and Multi-Variate Network Meta-Analysis Evaluating Pharmacological Agents.Journal of clinical medicine · 2025Review
- Redefining ventilator-associated pneumonia treatment: a novel economic analysis of tobramycin and colistin's cost-effectiveness.BMC pulmonary medicine · 2025Article
- Early Detection of Ventilator-Associated Pneumonia in a Neurosurgical Patient: Do Biomarkers Help Us?Cureus · 2025Article
- Article
- Prevalence of ventilator-associated pneumonia and associated factors among intubated adult patients admitted in public hospitals in Addis Ababa, Ethiopia: a facility-based retrospective study design.Frontiers in medicine · 2025Article
- Incidence and risk factors of ventilator-associated pneumonia in the intensive care unit: a systematic review and meta-analysis.Journal of thoracic disease · 2024Article
- Ventilator-associated pneumonia: pathobiological heterogeneity and diagnostic challenges.Nature communications · 2024Review
- Biofilm Formation by Hospital-Acquired Resistant Bacteria Isolated from Respiratory Samples.Journal of epidemiology and global health · 2024Article
- Epstein-Barr virus, Cytomegalovirus, and Herpes Simplex-1/2 reactivations in critically ill patients with COVID-19.Intensive care medicine experimental · 2024Article
- Carbapenem-ResistantTransboundary and emerging diseases · 2024Article
- Treatment and Management ofInfection and drug resistance · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ventilator-associated pneumonia (VAP) is the most frequent life-threatening nosocomial infection in intensive care units. The diagnostic is difficult because radiological and clinical signs are inaccurate and could be associated with various respiratory diseases. The concept of infection-related ventilator-associated complication has been proposed as a surrogate of VAP to be used as a benchmark indicator of quality of care. Indeed, bundles of prevention measures are effective in decreasing the VAP rate. In case of VAP suspicion, respiratory secretions must be collected for bacteriological secretions before any new antimicrobials. Quantitative distal bacteriological exams may be preferable for a more reliable diagnosis and therefore a more appropriate use antimicrobials. To improve the prognosis, the treatment should be adequate as soon as possible but should avoid unnecessary broad-spectrum antimicrobials to limit antibiotic selection pressure. For empiric treatments, the selection of antimicrobials should consider the local prevalence of microorganisms along with their associated susceptibility profiles. Critically ill patients require high dosages of antimicrobials and more specifically continuous or prolonged infusions for beta-lactams. After patient stabilization, antimicrobials should be maintained for 7-8 days. The evaluation of VAP treatment based on 28-day mortality is being challenged by regulatory agencies, which are working on alternative surrogate endpoints and on trial design optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.